Related references
Note: Only part of the references are listed.Cancer of Unknown Primary: Challenges and Progress in Clinical Management
Noemi Laprovitera et al.
CANCERS (2021)
Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer
Seyed Pairawan et al.
CLINICAL CANCER RESEARCH (2020)
ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy
Ryosuke Okamura et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Circulating Tumor Cell Clusters: United We Stand Divided We Fall
Samuel Amintas et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Next generation sequencing reveals CCNE1 amplification as an independent prognostic factor for triple negative breast cancer (TNBC) patients.
Xin Huang et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
NivoCUP: An open-label phase II study on the efficacy of nivolumab in cancer of unknown primary.
Junko Tanizaki et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
The mutational constraint spectrum quantified from variation in 141,456 humans
Konrad J. Karczewski et al.
NATURE (2020)
Comprehensive genomic profiling in FIGHT-202 reveals the landscape of actionable alterations in advanced cholangiocarcinoma.
Ian M. Silverman et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Clinical and immune profiling for cancer of unknown primary site
Koji Haratani et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Establishment and Characterization of a CTC Cell Line from Peripheral Blood of Breast Cancer Patients
Pan Zhao et al.
JOURNAL OF CANCER (2019)
KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC
Marika Cinausero et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2019)
ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade
Jianfeng Shen et al.
NATURE MEDICINE (2018)
Aggressive serous epithelial ovarian cancer is potentially propagated by EpCAM+CD45+ phenotype
Md Zahid Akhter et al.
ONCOGENE (2018)
Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts
Benjamin J. Drapkin et al.
CANCER DISCOVERY (2018)
The Tumor Suppressor ARID1A Controls Global Transcription via Pausing of RNA Polymerase II
Marco Trizzino et al.
CELL REPORTS (2018)
Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor-Positive Breast Cancer A Secondary Analysis of a Randomized Clinical Trial
Joseph Sparano et al.
JAMA ONCOLOGY (2018)
Prognostic impact of fibroblast growth factor receptor 2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers
Seyoung Seo et al.
ONCOTARGET (2017)
panelcn.MOPS: Copy-number detection in targeted NGS panel data for clinical diagnostics
Gundula Povysil et al.
HUMAN MUTATION (2017)
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Ahmet Zehir et al.
NATURE MEDICINE (2017)
Clinical and molecular characterization of patients with cancer of unknown primary in the modern era
A. M. Varghese et al.
ANNALS OF ONCOLOGY (2017)
Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary
Shumei Kato et al.
CANCER RESEARCH (2017)
Assessing the Pathogenicity of Insertion and Deletion Variants with the Variant Effect Scoring Tool (VEST-Indel)
Christopher Douville et al.
HUMAN MUTATION (2016)
SIFT missense predictions for genomes
Robert Vaser et al.
NATURE PROTOCOLS (2016)
Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro
K. Fizazi et al.
ANNALS OF ONCOLOGY (2015)
Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site New Routes to Targeted Therapies
Jeffrey S. Ross et al.
JAMA ONCOLOGY (2015)
Biology, detection, and clinical implications of circulating tumor cells
Simon A. Joosse et al.
EMBO MOLECULAR MEDICINE (2015)
Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors
R. Dienstmann et al.
ANNALS OF ONCOLOGY (2014)
Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality?
M. Ignatiadis et al.
ANNALS OF ONCOLOGY (2014)
Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis
Nicola Aceto et al.
CELL (2014)
Fibroblast Growth Factor Receptor 2 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Cholangiocarcinoma
Yasuhito Arai et al.
HEPATOLOGY (2014)
Colon Cancer, Version 3.2014
Al B. Benson et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2014)
A general framework for estimating the relative pathogenicity of human genetic variants
Martin Kircher et al.
NATURE GENETICS (2014)
MutationTaster2: mutation prediction for the deep-sequencing age
Jana Marie Schwarz et al.
NATURE METHODS (2014)
Cancer of Unknown Primary Site
Gauri R. Varadhachary et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Prognostic Value of FGFR Gene Amplification in Patients with Different Types of Cancer: A Systematic Review and Meta-Analysis
Jinjia Chang et al.
PLOS ONE (2014)
Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility
Min Yu et al.
SCIENCE (2014)
Predicting the Functional, Molecular, and Phenotypic Consequences of Amino Acid Substitutions using Hidden Markov Models
Hashem A. Shihab et al.
HUMAN MUTATION (2013)
Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy
Cigall Kadoch et al.
NATURE GENETICS (2013)
KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer
Y. Kawamoto et al.
BRITISH JOURNAL OF CANCER (2012)
A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets
Niantao Deng et al.
GUT (2012)
Circulating tumour cells in non-metastatic breast cancer: a prospective study
Anthony Lucci et al.
LANCET ONCOLOGY (2012)
FGFR2 Point Mutations in 466 Endometrioid Endometrial Tumors: Relationship with MSI, KRAS, PIK3CA, CTNNB1 Mutations and Clinicopathological Features
Sara A. Byron et al.
PLOS ONE (2012)
Circulating tumor cells: approaches to isolation and characterization
Min Yu et al.
JOURNAL OF CELL BIOLOGY (2011)
Predicting the functional impact of protein mutations: application to cancer genomics
Boris Reva et al.
NUCLEIC ACIDS RESEARCH (2011)
Gene Amplification CCNE1 Is Related to Poor Survival and Potential Therapeutic Target in Ovarian Cancer
Naomi Nakayama et al.
CANCER (2010)
Circulating tumor cells as a surrogate marker for determining response to chemotherapy in patients with advanced gastric cancer
Satoshi Matsusaka et al.
CANCER SCIENCE (2010)
A method and server for predicting damaging missense mutations
Ivan A. Adzhubei et al.
NATURE METHODS (2010)
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
Kai Wang et al.
NUCLEIC ACIDS RESEARCH (2010)
Fibroblast growth factor signalling: from development to cancer
Nicholas Turner et al.
NATURE REVIEWS CANCER (2010)
Identification of deleterious mutations within three human genomes
Sung Chun et al.
GENOME RESEARCH (2009)
Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer
Steven J. Cohen et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer:: A validation study of the CellSearch system
Sabine Riethdorf et al.
CLINICAL CANCER RESEARCH (2007)
Comparative analysis of the mutagenic activity of oxaliplatin and cisplatin in the Hprt gene of CHO cells
MJ Silva et al.
ENVIRONMENTAL AND MOLECULAR MUTAGENESIS (2005)
Circulating tumor cells, disease progression, and survival in metastatic breast cancer
M Cristofanilli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
